In an observational study, Cha et al. found that LDL cholesterol levels significantly increased after an SGLT2 inhibitor was used as add-on therapy, when compared with the effects of dipeptidyl-peptidase IV inhibitors in diabetes patients treated with metformin or sulfonylurea26. This evidence concerns the gene DPP4 and diabetes mellitus.